DERMATOP E EMOLLIENT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DERMATOP E EMOLLIENT (DERMATOP E EMOLLIENT).
Prednicarbate is a corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2, decreased release of arachidonic acid, and reduced synthesis of prostaglandins, leukotrienes, and other inflammatory mediators.
| Metabolism | Prednicarbate is metabolized primarily in the skin and systemically via esterases and cytochrome P450 enzymes, with prednisolone as a major metabolite. |
| Excretion | Predominantly hepatic metabolism; renal excretion of metabolites <5% unchanged; biliary/fecal excretion minimal. |
| Half-life | Terminal elimination half-life: 18-36 hours. Clinically, once-daily dosing maintains therapeutic effect. |
| Protein binding | >99% bound to plasma proteins (albumin and corticosteroid-binding globulin). |
| Volume of Distribution | Approximately 1.4 L/kg; indicates extensive tissue distribution, not restricted to plasma. |
| Bioavailability | Topical: 1-3% systemic absorption through intact skin; higher with occlusive dressing or damaged skin. |
| Onset of Action | Topical: 1-2 weeks for noticeable improvement in dermatologic conditions; maximal effect by 4 weeks. |
| Duration of Action | Duration: 24 hours with once-daily application; sustained effect with continued use. |
Apply a thin layer topically to affected areas twice daily. Maximum 3-week course.
| Dosage form | CREAM |
| Renal impairment | No adjustment required; systemic absorption is minimal. |
| Liver impairment | No adjustment required; local application with minimal systemic exposure. |
| Pediatric use | Not recommended for use in children under 3 months. For children 3 months to 18 years: apply a thin layer topically to affected areas once daily for up to 3 weeks. |
| Geriatric use | No specific adjustment required; use with caution due to increased potential for skin atrophy, telangiectasia, and other local adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DERMATOP E EMOLLIENT (DERMATOP E EMOLLIENT).
| Breastfeeding | It is not known whether prednicarbate is excreted in human milk after topical application. Systemic absorption is low; therefore, amounts ingested by infant are expected to be minimal. Caution is advised. Use on smallest area for shortest duration. No M/P ratio available. |
| Teratogenic Risk | Topical corticosteroids are considered low risk for teratogenicity when used at recommended doses. Systemic absorption is minimal with DERMATOP E EMOLLIENT (prednicarbate 0.1%). No adequate and well-controlled studies in pregnant women. Animal studies have shown corticosteroids to be teratogenic after systemic administration. In first trimester, avoid high potency or large areas. In second and third trimesters, use only if clearly needed, avoiding prolonged use on extensive areas or occluded skin. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to prednicarbate or any component of the formulation","Untreated bacterial, fungal, or viral skin infections"]
| Precautions | ["Systemic absorption may cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression","Local adverse reactions include skin atrophy, striae, telangiectasias, and secondary infections","Use with occlusive dressings increases systemic absorption","Avoid prolonged use on face, intertriginous areas, or in children"] |
Loading safety data…
| Fetal Monitoring | No specific monitoring required beyond routine prenatal care. If used on large areas or under occlusion, monitor for maternal skin atrophy, striae, or systemic effects. In fetus, no specific monitoring indicated. |
| Fertility Effects | No studies on fertility effects in humans. Animal studies with systemic corticosteroids have shown impairment of fertility. Topical use at recommended doses is unlikely to affect fertility. |